Den europeiske union - engelsk - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, non-small-cell lung - antineoplastic agents - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Den europeiske union - estisk - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Den europeiske union - finsk - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Den europeiske union - ungarsk - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - karcinóma, nem kissejtes tüdő - daganatellenes szerek - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Den europeiske union - nederlandsk - EMA (European Medicines Agency)

astrazeneca ab - reassortant influenzavirus (verzwakt levend) van de volgende stam: a / vietnam / 1203/2004 (h5n1) - influenza, human - vaccins - profylaxe van influenza in een officieel verklaarde pandemische situatie bij kinderen en adolescenten van 12 maanden tot jonger dan 18 jaar. pandemische influenza vaccin tegen h5n1 astrazeneca moet worden gebruikt in overeenstemming met officiële richtlijnen.

Den europeiske union - dansk - EMA (European Medicines Agency)

astrazeneca ab - reassortant influenzavirus (levende svækket) af følgende stamme: a / vietnam / 1203/2004 (h5n1) stamme - influenza, human - vacciner - profylakse af influenza i en officielt erklæret pandemisk situation hos børn og unge fra 12 måneder til under 18 år. pandemic influenza vaccine h5n1 astrazeneca bør anvendes i overensstemmelse med officielle retningslinjer.

Den europeiske union - dansk - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinom, ikke-småcellet lunge - antineoplastiske midler - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Den europeiske union - maltesisk - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Den europeiske union - bulgarsk - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - Карцином, недребноклетъчен белодроб - Антинеопластични средства - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Den europeiske union - litauisk - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.